ArticleJournal of family & reproductive health2025
Exploring the Genetic Influence of Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22) on Inflammatory Biomarkers in Endometriosis Progression.
Article in Journal of family & reproductive health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Investigating the genetic influence of Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22) on key inflammatory biomarkers-Interleukin-1β, Interleukin-6, and high-sensitivity C-reactive protein (hsCRP) and to evaluate their association with disease progression in endometriosis. Specifically, this study aims to (i) assess differential expression of PTPN22 in cases versus controls, (ii) examine correlations between PTPN22 expression and inflammatory markers, and (iii) determine the predictive value of these biomarkers using ROC curve analysis. Materials and methods: This study involved 150 women with endometriosis and 150 matched controls. Blood samples were analyzed for inflammatory markers (IL-6, IL-1β, hsCRP) using ELISA and PTPN22 gene expression by real-time PCR. Statistical analyses were conducted using Stata 17.0, and ethical approval (01/2022/ICEG) and informed consent was obtained. Results: PTPN22 expression was higher in endometriosis cases (p = 0.0001), suggesting a role in disease pathophysiology. ROC analysis showed moderate predictive accuracy (AUC = 0.63). Among the inflammatory markers, hs-CRP was the most diagnostic, followed by IL-6 and IL-1β, with stronger positive correlations observed in the endometriosis group. Conclusion: These findings highlight the translational relevance of PTPN22 and hsCRP as candidate biomarkers for early detection and risk stratification in endometriosis, underscoring the interplay between genetic susceptibility and inflammatory signaling in its pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.